ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 409-416

  Moriguchi Goto, Sayaka ^a   Yamashita, Atsushi ^a   Tamura, Noriko ^b   Soejima, Kenji ^c   Takahashi, Misaki ^a   Nakagaki, Tomohiro ^c   Goto, Shinya ^b   Asada, Yujiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

ADAMTS 13; Shear stress; Thrombogenesis; von Willebrand factor

Indexed keywords

COLLAGEN TYPE 1; DISINTEGRIN; FIBRIN; POLYMER; THROMBOSPONDIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE HEART INFARCTION; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BALLOON CATHETER; BLOOD FLOW; CORONARY ARTERY THROMBOSIS; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMORAL ARTERY; INTIMA; MALE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FUNCTION; RABBIT; SHEAR RATE; SHEAR STRESS; SURFACE PROPERTY; THROMBOCYTE ADHESION; THROMBOGENESIS;

ADAM PROTEINS; AGED; AGED, 80 AND OVER; ANIMALS; ATHEROSCLEROSIS; COLLAGEN TYPE I; CORONARY VESSELS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; RABBITS; THROMBOSIS; THROMBOSPONDINS; VON WILLEBRAND FACTOR;

EID: 62649108790     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.043     Document Type: Article

References (32)

1. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. Circulation 94 (1996) 2013-2020
2. Cosemans J.M., Kujipers M.J., Lecut C., et al. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 181 (2005) 19-27
3. Ruggeri Z.M. Perspective series: Cell adhesion in vascular biology. von Willebrand factor. J Clin Invest 99 (1997) 559-564
4. Hoshiba Y., Hatakeyama K., Tanabe T., Asada Y., and Goto S. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haematol 4 (2006) 114-120
5. Yamashita A., Sumi T., Goto S., et al. Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. Am J Cardiol 97 (2006) 26-28
6. Yamashita A., Furukoji E., Marutsuka K., et al. Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery. Arterioscler Thromb Vasc Biol 24 (2004) 2420-2424
7. Sporn L.A., Marder V.J., and Wagner D.D. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 46 (1986) 185-190
8. Levy G.G., Motto D.G., and Ginsburg D. ADAMTS13 turns 3. Blood 106 (2005) 11-17
9. Shelat S.G., Ai J., and Zheng X.L. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assay. Semin Thromb Hemost 31 (2005) 659-672
10. Moake J.L. Thrombotic microangiopathies. N Engl J Med 347 (2002) 589-600
11. Chauhan A.K., Motto D.G., Lamb C.B., et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 203 (2006) 767-776
12. Banno F., Kokame K., Okuda T., et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 107 (2006) 3161-3166
13. Donadelli R., Orje J.N., Capoferri C., Remuzzi G., and Ruggeri Z.M. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. Blood 107 (2006) 1943-1950
14. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106 (2002) 1893-1900
15. Goto S., Tamura N., Handa S., Arai M., Kodama K., and Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 106 (2002) 266-272
16. Soejima K., Nakamura H., Hirashima M., Morikawa W., Nozaki C., and Nakagaki T. Analysis on the molecular species and concentration of circulating ADAMTS13 in blood. J Biochem 139 (2006) 147-154
17. Kokame K., Nobe Y., Kokubo Y., Okayama A., and Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129 (2005) 93-100
18. Furlan M., Robles R., and Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 (1996) 4223-4234
19. Vischer U.M. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 4 (2006) 1186-1193
20. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L.H., and Hellums J.D. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 78 (1986) 1456-1461
21. He S., Cao H., Magnusson C.G.M., et al. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein. Thromb Res 103 (2001) 241-248
22. Yoo G., Blomback M., Schenck-Gustafsson K., and He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation. Br J Haematol 121 (2003) 123-129
23. Kaikita K., Soejima K., Matsukawa M., Nakagaki T., and Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 4 (2006) 2490-2493
24. Majerus E.M., Anderson P.J., and Sadler J.E. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 280 (2005) 21773-21778
25. Nishio K., Anderson P.J., Zheng X.L., and Sadler J.E. Binding of platelet glycoprotein Ib alpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A 101 (2004) 10578-10583
26. Back L.D., Radbill J.R., and Crawford D.W. Analysis of pulsatile viscous blood flow through diseased coronary arteries of man. J Biomech 10 (1977) 339-353
27. Sugimoto M., Matsui H., Mizuno T., et al. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood 101 (2003) 915-920
28. Dong J.F., Moake J.L., Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100 (2002) 4033-4039
29. Munnix I.C., Kuijpers M.J., Auger J., et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol 27 (2007) 2484-2490
30. Siedlecki C.A., Lestini B.J., Kottke-Marchant K.K., Eppell S.J., Wilson D.L., and Marchant R.E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88 (1996) 2939-2950
31. Tao Z., Peng Y., Nolasco L., et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 106 (2005) 4139-4145
32. Soejima K., Matsumoto M., Kokame K., et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 102 (2003) 3232-3237